Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
One of the most important aspects of the mucosal immune system in clinical medicine is its role in the development of obstructive airway disease. Although the mucosal immune system is undoubtedly crucial to the survival of humans, certain illnesses are probably a result of an inability to regulate selected components of the immune response occurring at mucosal sites, particularly in the airway. In contrast to recurrent bacterial pneumonia and repeated infections of the sinuses and middle ear cavities, which occur in individuals with immunologic deficits expressed at mucosal sites, wheezing and airway hyperreactivity induced by viral infections occur in individuals who are unable to regulate certain immune pathways but are otherwise immunologically intact. As a result of this disregulation, viral bronchiolitis in infancy and asthma later in life are associated by common and today well-recognized histopathologic features, including an exuberant inflammation of the lower airway mucosa. Although many inflammatory cells appear to be involved, this inflammatory response is quite unique because the airway mucosa is infiltrated by T lymphocytes of the T helper type 2 (Th2) phenotype and by eosinophils. The composition of this cellular response is dependent upon the discrete target-cell selectivity of chemotactic molecules. Cytokines, chemokines, and colony-stimulating factors (CSFs) generated and released by structural cells of the airways such as epithelial cells regulate the migration and activation of leukocytes and therefore play a crucial role in inflammatory processes of the lung.

In this chapter, we illustrate the clinical importance of virus-induced wheezing and airway hyperreactivity (referred to herein as infectious asthma), review the evidence that is in support of the role of the immune system in provoking these illnesses, and summarize experimental data on the inducible expression of epithelial cell cytokines by respiratory viruses.

**Epidemiology of Infectious Asthma**

Wheezing induced by infectious agents occurs with a frequency of 11 cases per 100 children in the first year of life, 6 cases per 100 children in the second year, and 1.3 cases per 100 children in the third year (Denny and Clyde, 1986). The most severe forms of illness are observed in infants between 2 and 3 months of age (Brandt et al., 1973). Illness is both more common and more severe in males until the age of 9 years when the incidence becomes similar between the sexes (Denny and Clyde, 1986). Respiratory syncytial virus (RSV), the parainfluenza viruses, and influenza viruses are probably the most important causes of infectious asthma in infancy, whereas rhinoviruses predominate as a cause of milder outpatient wheezing in older children (Table 83.1). Similar studies have been completed in adults. In a study of 138 asthmatic adults, 89% (223/250) of colds were associated with exacerbations of asthma (Nicholson et al., 1993). In 115 laboratory-confirmed cases of viral or chlamydial
infection, 28 (24%) episodes occurred in which peak expiratory flows fell by 50 ml/min or greater. Rhinoviruses are presumed to be the most important etiologic agents in adults. In the studies mentioned earlier, infection was documented by culture or serologic means. Neither of these techniques is efficient for identification of viral infections, so the actual importance of viral infections may have been underestimated. One study used polymerase chain reaction amplification of nucleic acids to identify infecting agents in children with acute episodes of obstructive airway disease. Viruses or chlamydiae could be detected in 80% of episodes in which children experienced reductions in peak expiratory flow rates (Johnston et al., 1995).

Table 83.1. Role of Various Agents in Infectious Asthma—Relative Order of Importance by Age Group

| Age Group   | Agents Selected Based on Relative Order of Importance |
|-------------|------------------------------------------------------|
| Infants     | Respiratory syncytial virus, parainfluenza viruses (especially type 3), influenza viruses |
| Preschool children | Respiratory syncytial virus, parainfluenza viruses, rhinovirus, coronaviruses |
| Adolescents | Rhinoviruses, mycoplasma pneumoniae, parainfluenza viruses, respiratory syncytial viruses |
| Adults      | Rhinoviruses, parainfluenza viruses, mycoplasma pneumoniae, chlamydia pneumoniae |

PRINCIPAL AGENTS RESPONSIBLE FOR INFECTIOUS ASTHMA

An impressive amount of information has been gathered concerning the role of the immune system in RSV, influenza, and rhinovirus infections, with regard to mechanisms of eradication of primary infection, pathogenesis of severe disease, and prevention of reinfection. A review of the immune response to infection with these specific agents provides an overall perspective that can probably be applied to infection with other viral agents.

Respiratory syncytial virus

Clinical presentation

RSV is the major cause of serious lower respiratory disease in infancy and early childhood. An estimated 28 episodes of lower respiratory disease caused by RSV occur for every 100 children followed through the first 12 months of life. Reinfections in the second year of life are extremely common and occur with substantial frequency at all ages (Glezen et al., 1986). Therefore, although most individuals develop relatively mild symptoms at the time of RSV infection, certain individuals seem more prone to develop lower respiratory illness (in particular, bronchiolitis) at the time of RSV infection. The fact that bronchiolitis (as well as croup) can be seen with a wide variety of viral agents suggests that the development of these illnesses is not entirely specific to any feature of RSV but to a similar feature of a variety of viruses as well as to some unique host component.

Inoculation of RSV occurs through the nasal mucosal surface or through the eye (Hall et al., 1981). The incubation period is assumed to be at least 4–5 days, at which time the infected child develops symptoms of rhinorrhea, nasal obstruction, and low-grade fever. In most patients, the illness resolves over 7–10 days, but in others the cough becomes progressive and eventually signs of lower respiratory tract involvement appear. At this point, secretions are profuse and contain 10^5–10^6 infectious units of virus per milliliter of secretion (Hall et al., 1976). In cases of pneumonia, descent of virus to the lower respiratory tract probably occurs as a result of aspiration. In the syndrome of bronchiolitis, whether disease is entirely the result of spread of virus to the bronchioles or occurs through stimulation of pathologic immune responses simultaneously is not yet clear. In any case, the child at this point manifests respiratory distress that may be severe. Nasal flaring, dyspnea, and retractions are noted, and auscultation of the chest reveals rhonchi and harsh wheezing. Otherwise, the child remains remarkably free of other symptoms. Fevers are usually not marked, and the child may be quite active despite the presence of moderate hypoxia, again suggesting that severe illness may be mediated, at least in part, by mechanisms other than progressive viral infection.

Histopathology

The histologic picture of RSV pneumonia reveals mononuclear cells within the alveolar walls and small airways. Engorgement of the capillary bed with edema is also noted. Lymphocytes and plasma cells are recruited into alveolar walls. The alveolar walls may become increasingly thick and filled with proteinaceous material, and intranuclear or cytoplasmic inclusions and giant cells may be observed (Aherne et al., 1970). Bronchiolitis, in contrast, is characterized by necrosis and sloughing of the respiratory epithelium and plugging of the small bronchioles with fibrin and mucus. An intense peribronchial infiltration of lymphocytes and plasma cells occurs, with considerable edema. Localized hyperinflation due to airflow obstruction is characteristic, and atelectasis is common.
Immune response
The precise role of RSV-specific antibody in recovery from primary infection is controversial. Local antibody responses, predominantly in the secretory IgA class, appear in the respiratory tract shortly after the onset of primary infection (McIntosh et al., 1979; Kaul et al., 1981). In some studies (McIntosh et al., 1979), viral shedding is terminated at about the time of the appearance of antibody in secretions. However in other studies (Kaul et al., 1981), antibody is present at a time when substantial quantities of virus are still recoverable from the respiratory tract. Thus the role of specific secretory IgA antibody in termination of infection is uncertain. Although repeated infection tends to result in accelerated local antibody responses (Kaul et al., 1981) and reduced severity of illness, whether local antibody is responsible for protection is not clear. In one study of adults undergoing experimental RSV challenge, specific nasal IgA antibody titers did not correlate with protection against infection (Hall et al., 1991). In other investigations (Mills et al., 1971), neutralizing activity in nasal secretions apparently correlated with partial resistance to infection. However, subsequent studies (McIntosh et al., 1979) demonstrated that such neutralizing activity is not necessarily antibody. In summary, RSV-specific secretory IgA antibody present at the time of infection does not prevent reinfection but may reduce the degree of viral replication.

Serum-neutralizing antibody may be more effective in providing immunity. In a study of adults experimentally challenged with RSV, preexisting titers of neutralizing antibody in serum (but not in secretions) provide some degree of protection against infection. A hyperimmune human antisera against RSV has been prepared by plasmapheresis of donors selected on the basis of having high-serum RSV-neutralizing antibody titers. When infected on a monthly basis to infants at high risk of serious RSV infection, this compound reduced the rate of RSV-related hospitalization by 40% (The PREDVENT Study Group, 1997). Therefore, serum antibody, presumably appearing in the respiratory tract by transudation following infection with RSV, appears to be better associated with protection against detectable infection than locally synthesized IgA antibody. Nevertheless, even the highest titers of antibody in serum or respiratory secretions do not seem to provide absolute protection against RSV, because as many as 25% of adults can be infected despite very high antibody titers (Mills et al., 1971; Hall et al., 1991).

Cell-mediated immune mechanisms may also be important in recovery from RSV infection. Individuals with congenital or acquired defects in cell-mediated immune function shed virus for prolonged periods and seem to have a greater frequency of development of pneumonia than immunologically intact individuals (Fishaut et al., 1980; Hall et al., 1986). T lymphocytes expressing cytotoxic activity against RSV-infected cells have been demonstrated in the peripheral blood of human infants and appear at about the time that viral shedding begins to decrease (Issacs et al., 1987; Chiba et al., 1989; Mbawuike et al., 2001). Cytotoxic cells are CD8+, and cytotoxic activity appears to be MHC restricted in that is expressed only against cells infected with RSV, and not with other viruses. The cytotoxic activity of these cells correlates directly with their IFNγ expression and inversely with IL4 expression. The role of these cells in protection and pathogenesis remains uncertain, and no studies of lymphocytes obtained from the respiratory tract have been completed.

Bronchial reactivity
Potential mechanisms by which certain viruses may induce airway hyperreactivity and obstructive airway disease are included in Table 83.2. RSV-specific IgE antibody responses have been documented in respiratory secretions and sera of infants and young children undergoing natural RSV infection (Welliver et al., 1980, 1981; Bui et al., 1987; Russi et al., 1993; Rabatic et al., 1997; Aberle et al., 1999). As with secretory IgA, IgE appears first bound to the surface of RSV-infected cells and later free in secretions (Welliver et al., 1980, 1981). Higher concentrations of RSV-IgE were observed in infants with bronchiolitis in comparison with infants with upper respiratory illness alone (Welliver et al., 1981; Bui et al., 1987). RSV-specific IgE titers in respiratory secretions were also associated with greater degrees of hypoxia at the time of acute infection, suggesting that both the form and severity of illness are partially determined by the magnitude of RSV-IgE responses. Histamine can be detected in both the respiratory secretions and plasma of infants with RSV bronchiolitis, further substantiating the role of immediate hypersensitivity responses in RSV infection. Leukotrienes, particularly LTC4, have been identified in the respiratory secretions of infants with RSV infection (Volovitz et al., 1988; Garofalo et al., 1991; van Schaik et al., 1999). Although a direct correlation of the leukotriene content of secretions with severity of illness was not observed, these compounds may nevertheless contribute to the airway obstruction that occurs with RSV infection.

Although autopsy studies of infants with fatal RSV infection do not reveal the presence of eosinophils in the airway, nevertheless eosinophil cationic protein, a component of eosinophil granules that is toxic to respiratory epithelium, has been detected by several investigators in respiratory secretions of infants with RSV infection (Garofalo et al., 1992; Ingram et al., 1995; Garofalo et al., 1994). Eosinophilia in peripheral blood is suppressed at the time of RSV infection, although the suppression is overcome somewhat in subjects with bronchiolitis, particularly males. It is possible that eosinophils present in the respiratory mucosa have degranulated at the time of RSV infection and were not replaced by the time of autopsy in the fatal cases. Thus, although eosinophils certainly degranulate in the respiratory tract during RSV infection, the exact role of eosinophils in RSV infection is uncertain, especially because some preliminary observations suggest that degranulation of eosinophils occurs only after lower airway obstruction has been established (R.C. Welliver, personal communication, 1998). On the other hand, recent studies demonstrate that eosinophils exposed to RSV are able to secrete inflammatory cytokines (Olszewski-Pazdrak et al., 1998a) and, when cultured in the
presence of RSV-infected airway epithelial cells, to release eosinophil cationic protein (Olszewska-Pazdrak et al., 1998b).

Evidence also suggests that exaggerated T-cell responses may result in enhanced lung disease following RSV infection. Reconstitution of RSV-infected mice with cytotoxic T cells that have been repeatedly stimulated with RSV antigen clears virus rapidly from lungs but results in enhanced mortality and increases histopathologic changes in the lungs (Cannon et al., 1988). Whether similar events occur in humans is not known, but infants with RSV bronchiolitis have been reported to have peripheral blood lymphocytes that are more responsive to RSV antigen than similar cells from infants with upper respiratory infection alone because of RSV (Welliver et al., 1979). In addition, recipients of an inactivated RSV vaccine developed evidence of cell-mediated hypersensitivity to RSV after vaccination and subsequently developed enhanced lung disease when naturally infected with RSV (Kim et al., 1976).

In asthma, certain evidence suggests that airway disease is a result of overexpression of T-helper type 2 (Th2) cytokines such as IL4, IL5, and IL13, especially because these cytokines are important in the synthesis of IgE antibody and in migration and activation of eosinophils, the predominant airway inflammatory cell in asthma. In mice previously vaccinated with the formalin-inactivated vaccine that enhanced disease in humans, RSV infection causes increased expression of mRNA for IL5 and IL13 (Waris et al., 1996). In humans, polymorphisms of IL4 genes have been associated with more severe forms of RSV-related illness (Choi et al., 2002; Hoebee et al., 2003). However, stimulation of lymphocytes from RSV-infected humans causes the expression of mRNA for the Th1 cytokine IFNg primarily, little IL4 expression, and essentially no increase in IL5 or IL13 (Anderson et al., 1994; Mbawuike et al., 2001; Tripp et al., 2002). This pattern is reflected in studies that measured cytokine protein in secretions of RSV-infected infants. In these studies, IFNg predominated, whereas smaller amounts of IL4 were detected, and IL5 and IL13 were only rarely detected in infants with bronchiolitis (van Schaik et al., 1999; Garofalo et al., 2001). Although IFNg is the predominant cytokine present in bronchiolitis, there is some evidence that infants with the most severe forms of illness have lesser IFNg responses than those with milder forms of bronchiolitis (Aberle et al., 1999; Bont et al., 1999; Garofalo et al., 2001; Johnston et al., 2002).

| Mechanism                                                                 | Virus                        | References |
|--------------------------------------------------------------------------|-----------------------------|------------|
| Sloughing of airway epithelium with: Exposure of irritant receptors      | Parainfluenza, rhinovirus   | Empey et al. (1976), Fryer and Jacoby (1991) |
| Sloughing of airway epithelium with: Loss of inhibitory mediators and cholinergic overactivity | Parainfluenza, influenza     | Vanhoutte et al. (1989), Nadel et al. (1991) |
| Sloughing of airway epithelium with: Increased permeability and sensitization to allergens | RSV, parainfluenza          | Freihorst et al. (1988), Leibovitz et al. (1989), Riedel et al. (1996), Schwarze et al. (1997) |
| Antiviral immune response                                                | RSV, parainfluenza          | Welliver et al. (1981), Welliver et al. (1982), Bui et al. (1987), Russi et al. (1993), Rabatic et al. (1997), Aberle et al. (1999) |
| T cell-mediated (CD4+ and/or CD8+; Th1 and/or Th2)                       | RSV, rhinovirus, influenza   | Openshaw et al. (1995), Corne and Holgate (1997), Neuzil and Graham, (1996) |
| Airway mucosa inflammation                                               | RSV, rhinovirus, influenza   | Volovitz et al. (1988), Garofolo et al. (1991), Proud et al. (1990) |
| Eosinophil and basophil degranulation                                     | RSV, rhinovirus              | Garofolo et al. (1992), Ingram et al. (1995), Welliver et al. (1981), Smith and Remingo (1982), Igarshi et al. (1993) |
| Epithelial-derived cytokines                                             | (See Table 83.3)            |            |

Table 83.2. Potential Mechanisms by which Respiratory Viruses Cause Airway Obstruction

*Incomplete list of original and review articles.*
Although there are little data to support a role for the IL5 and IL13 in bronchiolitis, certain chemokines that have the same biologic effects are present in RSV-infected infants (Sheeran et al., 1999). The chemokines RANTES (regulated on activation, normal T-lymphocyte expressed and secreted) and MIP (macrophage inflammatory protein) 1-alpha and 1-beta can attract lymphocytes and eosinophils, and activate mast cells and basophils (Kuna et al., 1998). Alternatively, they may be synthesized by Th1 lymphocytes (Schrum et al., 1996). RSV infection induces expression of mRNA for these chemokines, as well as their appearance in the respiratory tract (Garofalo et al., 2001; Tripp et al., 2002). Overexpression of these chemokines may then result in more severe forms of bronchiolitis (Garofalo et al., 2001).

**Influenza virus**

**Clinical presentation**

Influenza viruses are responsible for yearly outbreaks of respiratory illness among all age groups. The highest mortality rates are observed in infants and in the elderly. Characteristic “flu-like” symptoms include fever, headache, intense myalgia, and prolonged malaise. Cough may or may not be a prominent finding, especially early in the illness. The principal sites of involvement in most influenza virus infections are the trachea and the bronchi. As with RSV infections, lower respiratory tract illnesses such as pneumonia or wheezing are not as common in otherwise healthy persons. Nevertheless, group and bronchiolitis may occur in infancy and pneumonia may occur at any age.

**Histopathology**

Influenza infection of the respiratory tract results in swelling and desquamation of infected ciliated cells. Airway edema and infiltration by mononuclear and polymorphonuclear cells follows, with extensive sloughing to the layer of the basal cells. Influenza pneumonia is characterized by hemorrhagic alveolar infiltrates, formation of hyaline membranes, and marked lymphocytic infiltration of the interstitium and alveolar walls (Kilbourne, 1987).

In contrast to infection with RSV and most other viruses, influenza infection is accompanied by an increased frequency of bacterial superinfection that may be the result of reduced mucociliary clearance following influenza virus infection (Camner et al., 1973), greater damage to the mucosa with resultant diminished resistance to bacterial invasion (Kilbourne, 1987), or suppression of activity of phagocytic cells (Casali et al., 1984; Hartshorn and Tauber, 1988).

**Protective immune response**

Initial infection with one strain of influenza virus provides partial immunity to reinfection with the same strain. Such homotypic reinfections are generally asymptomatic (Frank et al., 1979; Sonoguchi et al., 1986). Resistance to reinfection has been attributed to the presence of antibody in serum or respiratory secretions; high titer of antibody at either site are capable of conferring resistance (Clements et al., 1986). Whether local or serum antibody is most efficient in providing protection against reinfection in humans is uncertain.

Antibody to the hemagglutinin of influenza appears to contribute to immunity by preventing attachment of the virus to the respiratory epithelium, whereas antibody to the neuraminidase antigen inhibits cleavage of preformed virus from the cell membrane (Ogra et al., 1977). Virtually no data are available on the role of serum or secretory antibody in recovery from primary influenza virus infection. Minor changes in hemagglutinin structure by variation in amino acid sequences (“antigenic drift”) or major changes via genetic reassortment (“antigenic shift”) enable the virus to infect previously exposed individuals.

The role of cell-mediated immunity in influenza virus infection has been extensively investigated in mice and, to a lesser extent, in humans. Transfer of primary or secondary influenza-immune splenic cells to mice infected intranasally with influenza virus results in significant clearance of virus from the lung and protection against death in the recipients. T lymphocytes represent the cell population primarily responsible for this immunity (Yap and Ada, 1978). Evidence suggests that the pathogenesis of influenza virus infection may be a reflection of the cell-mediated immune response in the lung. First, influenza virus replicates in and is released from the cells without causing cell death. Second, mice without functioning T cells develop extensive replication of virus in the lung with dissemination to other organs but develop minimal pulmonary infiltration following influenza virus challenge (Wyde et al., 1977). In contrast, cytotoxic T cells appear in the lungs of immunocompetent mice at the peak of respiratory symptoms and when histopathology in the lung is most prominent (Ennis et al., 1977).

Although such definitive studies have not been repeated in humans, cytotoxic T-cell responses develop in humans after influenza virus infection. Maximal responses occur in the second week after infection (Greenberg et al., 1978). These cytotoxic cells apparently recognize all influenza type A strains but not influenza viruses of other types or noninfluenza viruses. These cytotoxic cells appear to be HLA restricted and are apparently capable of providing protection against subsequent influenza virus infection, even when influenza-specific serum antibody is undetectable in serum or secretions. These cytotoxic responses are apparently short lived, because only 30% of individuals exposed to a given strain of influenza virus had inducible cytotoxic T-cell activity when tested 5 years later (McMichael et al., 1983). The majority of the cytotoxic T-cell responses appear to be mediated by CD8+ cells with major histocompatibility complex (MHC) restriction class I (Fleischer et al., 1985; Yamada et al., 1986).

In addition to specific cytotoxic T cells, nonspecific natural killer cell activity also increases after influenza virus infection in humans. However, the same increase in natural killer activity is observed in humans who continue to shed virus as in those individuals who do not continue to shed virus (Ennis et al., 1981). A sufficiently large viral inoculum may be able to overcome natural killer cell resistance.
Rhinoviruses

Therefore, although data on mucosal cell-mediated immune responses are lacking, cytotoxic T cells circulating in the blood appear to be important in restricting primary viral infection as a result of RSV and influenza and probably other viruses. These cytotoxic cells may play some role in protection against reinfection and are almost undoubtedly responsible for much of the histopathology seen with viral infections of the lung. There is some evidence that exaggerated T-cell responses may be responsible for unusually severe forms of infection due to both RSV and influenza virus.

**Bronchial reactivity**

Increased bronchial reactivity is a frequent complication of influenza infection (Little et al., 1978; Laitenen and Kava, 1980). The increase in bronchial reactivity is associated with loss of the epithelium and may be due to either exposure of airway irritant receptors (Empye et al., 1976) or a loss of natural inhibitors of airway reactivity (Jacoby et al., 1988). The roles of influenza-specific IgG responses, other inflammatory responses, and mediator release have not been extensively evaluated for a possible role in inducing bronchial hyperreactivity, presumably because the principal morbidity and mortality resulting from influenza virus infection is not manifested by airway obstruction. Nevertheless, MIP1α is required for induction of inflammatory responses in animal models of influenza virus infection (Cook et al., 1995), and influenza infection of epithelial cells and monocytes results in the release of many of the chemokines described previously for RSV infection (Matsukura et al., 1996, 1998; Sprenger et al., 1996).

**Rhinoviruses**

**Clinical presentations**

Rhinoviruses are the most frequently identified agents causing the common cold. Attack rates in the general population are in the range of 0.42–0.64 infections per person per year, with higher rates in children. Infections occur more commonly in the spring and autumn but can be documented year-round (Fox et al., 1985). Although most infections are trivial, nevertheless, rhinoviruses are recognized as the most frequent causes of asthma exacerbations in school-aged children and adults (Nicholson et al., 1993; Johnston et al., 1995).

**Histopathology**

Because of the mild nature of rhinovirus infections, autopsy materials are limited. Nasal biopsies have been performed in a small number of individuals with natural or experimental rhinovirus infection. These reports describe minimal damage to epithelial cells in rhinovirus colds (Winther et al., 1986) and detection of only a few infected cells using nuclear probe techniques (de Arruda et al., 1991). This implies either that very few cells become infected or that infected cells exfoliate quickly and are rapidly replaced. Nasal biopsies also reveal minimum to no changes in the number of inflammatory cells in tissue from infected individuals in comparison to preinfection samples (Fraenkel et al., 1994). In contrast to these tissue samples, neutrophils are abundant in nasal lavage fluids obtained from infected subjects. The degree of upper respiratory symptoms correlates with the number of invading neutrophils, and with the release of kinins in nasal secretions (Naclerio et al., 1988). However, it remains uncertain whether the magnitude of the neutrophil and kinin responses simply reflects the degree of inflammation or is actually responsible for the manifestations of illness. Mucosal biopsies from individuals with rhinovirus colds show modest infiltration with lymphocytes and eosinophils (Fraenkel et al., 1995).

**Immune response**

Rhinovirus-specific antibody responses occur both in the respiratory tract and in serum following rhinovirus infection, but the nature of these responses has not been investigated extensively. In experimental infection, responses become detectable 2 to 3 weeks after inoculation (Barclay et al., 1989). Serum antibody responses are greater and more prolonged in adults than in children, suggesting that reinfection occurs and gradually induces solid immunity (Fox et al., 1985).

Cell-mediated responses also occur following infection. Tonsillar lymphocytes proliferate in response to stimulation with rhinovirus antigens if antigen-presenting cells are present (Wimalasundera et al., 1997). The responding cells are CD4+ and produce interleukin-2 (IL-2) and interferon gamma, but not IL-4. In peripheral blood, the number of CD4+ cells is reduced, suggesting they migrate to the respiratory tract in response to infection (Lewandowski et al., 1986). Upon restimulation in vitro, peripheral blood cells release IL-2, and the magnitude of this response correlates inversely with virus shedding and with nasal mucus scores. These cells also release interferon gamma, but the quantity of this cytokine produced did not correlate with virologic or clinical parameters (Hsia et al., 1990). In two other studies, the amount of IFNγ present either before (Parry et al., 2000) or during (Gern et al., 2000) rhinovirus infection was related to the peak titer and duration of rhinovirus shedding.

Studies of Th1 and Th2 cytokines are limited to date. However, peripheral blood lymphocytes recovered from rhinovirus-infected subjects and stimulated with rhinovirus release IFNγ (before and after infection) but not IL5 (Parry et al., 2000). Ratios of IFNg/IL5 do not change markedly over the course of experimental rhinovirus colds (Gern et al., 2000). Higher IFNg/IL5 ratios were associated with reduced cold symptoms in this study.

**Airway reactivity**

The mechanism by which rhinoviruses result in lower respiratory disease is still unclear. Rhinovirus infection of nonallergic individuals does not alter forced expiratory flows (FEV1) nor increase airway reactivity to histamine (Fraenkel et al., 1995; Halperin et al., 1983; Lemanske et al., 1989; Calhoun et al., 1991, 1994). Even in subjects with allergic rhinitis or mild asthma, rhinovirus infection apparently does not alter lung function (Fraenkel et al., 1995; Lemanske et al., 1989; Calhoun et al., 1991, 1994), indicating that simple infection with this virus is insufficient to cause airway obstruction and wheezing.
The question of whether rhinovirus infection induces changes in airway reactivity in atopic individuals has been extensively investigated. Most studies have determined that airway responsiveness to histamine and to allergens is increased in atopic subjects (Lemanske et al., 1989; Grunberg et al., 1997a, 1997b; Gern et al., 1997). This suggests that rhinovirus infection might provoke wheezing only in those individuals who are atopic. This would presumably occur by increasing the reactivity of the airway, so that the degree of obstruction following allergen exposure would be enhanced during acute rhinovirus infection. Rhinovirus infection does not apparently increase the reactivity of the airway to bradykinin, which is a potent stimulus of sensory nerves. Therefore, the increase in airway reactivity induced by rhinovirus infection is probably not due to an increased exposure of sensory nerves (Grunberg et al., 1997a).

Even though rhinovirus infections may increase airway reactivity in atopic individuals, it cannot be concluded that this is sufficient to result in airway obstruction. Indeed, subjects with allergic rhinitis (but not asthma) develop increases in airway reactivity following rhinovirus infection but do not wheeze or manifest other evidence of airway obstruction. Symptomatic airway obstruction following rhinovirus infection must have another basis.

Pertinent data in this regard have been generated (Lemanske et al., 1989; Calhoun et al., 1991, 1994), in which both normal individuals and those with ragweed-induced allergic rhinitis are experimentally infected with rhinovirus or given a placebo. Each group is then challenged with ragweed antigen E by instilling the antigen directly into the lung via an endoscope. No change in pulmonary function (FEV1 or FVC) occurs in these individuals. However, the group infected with rhinovirus and challenged with allergen develops increased airway reactivity. More importantly, late phase asthmatic responses (LARs), defined as a fall in FEV1 occurring at 48 hours after allergen challenge, developed in the majority of individuals infected with rhinovirus, but not in the uninfected group (Lemanske et al., 1989; Calhoun et al., 1991). These results indicate that rhinovirus infection may not result directly in airway obstruction. However, they do suggest that atopic individuals are more likely to develop airway obstruction if they encounter an allergen to which they are sensitive during acute rhinovirus infection.

Further studies from the same group attempted to determine the mechanism by which rhinovirus infection enhances the potential for allergen-induced airway obstruction. The results of these studies indicate that histamine release in the airway and in the blood is increased following allergen challenge in atopic individuals infected with rhinovirus (Calhoun et al., 1991, 1994). The degree of histamine release is greater than that accounted for by the allergen challenge itself (Calhoun et al., 1991), suggesting that rhinovirus infection enhances the capability of inflammatory cells to release mediators following allergen exposure. Because the release of histamine, but not tryptase, is enhanced in these subjects, it appears that the primary effect of rhinovirus infection is on basophils recruited to the lung rather than mast cells residing in the lung. Again, rhinovirus infection in normal individuals did not result in abnormal histamine release in the airway or in the blood.

Rhinovirus was infrequently recovered from lung lavage fluids in these experiments, even though it was readily recovered from the nasopharynx of study participants. This implies that infection with rhinovirus that is limited to the upper respiratory tract may still cause enhanced reflex release of mediators of airway obstruction in the lower respiratory tract. These are important observations with regard to attempts to develop rhinovirus vaccines. For vaccines to be effective in preventing asthma induced by rhinoviruses, they may need to be capable of preventing rhinovirus infections absolutely rather than simply restricting them to the upper respiratory tract.

In summary, available data suggest that rhinovirus infections are important causes of lower respiratory disease primarily in individuals with underlying asthma. Even then, the principal effect of rhinovirus infections may be in enhancing the response to allergens to which the individual is sensitive. The precise mechanism appears to involve increased degradation of basophils, and perhaps eosinophils. In support of this are the autopsy findings in a child with fatal rhinovirus infection (Las Heras and Swanson, 1983). This 11-month-old infant had symptoms of asthma for 3 months before dying unexpectedly. Rhinovirus type 37 was recovered from both the lung and the blood. Lung findings at autopsy were consistent with acute asthma, including mucus plugging and eosinophil infiltration of the airways.

**AIRWAY MUCOSA INFLAMMATION IN RESPIRATORY VIRAL INFECTIONS**

**Human and animal models of RSV-associated disease**

In addition to the clinical and epidemiologic relationship between bronchiolitis in infancy and asthma later in life (Hall et al., 1984; Sigurs et al., 1995), the two diseases are linked by common histopathologic features characterized by profound inflammation of the airway mucosa. As mentioned earlier in this chapter, necrosis of the bronchial epithelium associated with peribronchial and perivascular mononuclear cell infiltration is considered a hallmark of RSV infection both in human (Aherne et al., 1970) and in animal models (Prince et al., 1986; Graham et al., 1988). Moreover, the presence of cell-specific inflammatory mediators in nasopharyngeal secretions of children with bronchiolitis suggests that RSV infection triggers the migration to the airways and local activation of eosinophil and basophil leukocytes (Welliver et al., 1981; Garofalo et al., 1992, 1994; Sigurs et al., 1994; Colocho Zelaya et al., 1994; Ingram et al., 1995).

**Epithelial cytokines**

The specific antiviral immune response appears to play a role in the pathogenesis of RSV-induced airway inflammation. However, several studies suggest that other mechanisms may also trigger and sustain lung inflammation following viral
infection. In this regard, although the defense against foreign organisms, such as viruses or bacteria, is mediated by innate and by specific acquired immunity, the effector phases of both natural and specific immunity are largely mediated by cytokines. These molecules operate in networks and produce a cascade of effects that contribute to the orchestration, development, and functions of the immune system. Cytokines such as IL-1α/β, IL-6, and tumor necrosis factor (TNF-α), mediate and regulate inflammatory responses that are often associated with the immune response (reviewed in Arai et al., 1990). IL-1, as an example, can induce cytokine genes, protein synthesis, and secretion in a wide variety of cell types and increase the expression of adhesion molecules on endothelial cells and modulate other cell surface molecules that are critical for cell-cell interaction and leukocyte migration (reviewed in Dinarello 1992).

In addition to the pivotal role of inflammatory cytokines, much of the cellular response at sites of tissue inflammation is controlled by gradients of chemotactic factors that direct leukocyte transendothelial migration and movement through the extracellular matrix. The composition of this cellular response is dependent on the discrete target-cell selectivity of chemotactic molecules. Chemokines, a newly identified family of small chemotactic cytokines, regulate the migration and activation of leukocytes and therefore play a key role in inflammatory processes of the lung (reviewed in Oppenheim et al., 1991). Two subfamilies, the CXC and the CC chemokines, are defined by the splicing of the conserved cysteine residues that are either separated by one amino acid (CXC chemokines) or are adjacent (CC chemokines). IL-8 and growth-related peptide (GRO)-α belong to the CXC family and are mainly chemotactic factors for neutrophils. However, members of the CC branch of the chemokine family such as RANTES (regulated upon activation, normal T cell expressed and presumably secreted), macrophage inflammatory protein-1α (MIP-1α), monocyte chemotactic protein (MCP)-1, MCP-3, MCP-4, and eotaxin are chemotactic factors for monocytes, basophils, and eosinophils, with virtually no activity on neutrophils. With regard to human T lymphocytes, RANTES, MIP-1α, and MCP-1 have been shown to be specifically chemotactic for CD4+ T cells of the CD45RO+ memory phenotype (reviewed in Baggioioli et al. 1997). The chemokine receptor CCR3, which binds eotaxin, RANTES, MCP-3, and MCP-4, has been found to be expressed by Th2 cells, but not by Th1 cells (Sallusto et al., 1997). The expression of CCR3 by Th2 cells is also functional because both eotaxin and RANTES-induced intracellular Ca²⁺ increase and chemotaxis by CCR3+ Th2 clones.

Colony-stimulating factors (CSFs) are growth factors that control proliferation of stem cells and differentiation along the granulocyte pathway. The CSFs are further defined by the types of granulocyte colonies they induce in culture and include neutrophil colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage colony-stimulating factors (GM-CSFs). GM-CSF is recognized as an important factor for stimulating hematopoiesis and prolonging eosinophil survival (Ruef and Coleman, 1990). It also enhances LTC4 release (Silberstein et al., 1986) and eosinophil cytotoxicity (Lopez et al., 1986). At high concentrations (produced locally during inflammation), GM-CSF can act as a true chemotaxon for eosinophils and can directly mediate eosinophil migration (Warringa et al., 1991).

The respiratory epithelium represents the principal cellular barrier between the environment and the internal milieu of the Airways. Epithelial damage and loss of integrity are a recognized feature of asthma (Jeffery et al., 1989) and are thought to be associated with the increased bronchial hyperresponsiveness that is characteristic of the disease (Boushey et al., 1980). In addition, during the last few years it has become clear that the epithelium, after contact with exogenous stimuli such as microbial infections, can actively modulate the local inflammatory and immune responses by releasing a variety of mediators and cytokines. In this regard, human airway epithelial cells appear to be a dominant source of CC chemokines including RANTES (Stellato et al., 1995), MCP-1 (Standiford et al., 1991), MCP-4 (Stellato et al., 1997), and eotaxin (Lilly et al., 1997), and, among the CSFs, of GM-CSF (Ohtoshi et al., 1991; Cromwell et al., 1992).

**Epithelial cytokines and respiratory viruses (in vitro)**

Respiratory epithelial cells are the primary target of viruses that enter the Airways. RSV infection results from inhalation or self-inoculation of the virus into the nasal mucosa followed by infection of the local respiratory epithelium. Spreading along the respiratory tract occurs mainly by cell-to-cell transfer of the virus along the intracytoplasmic bridges (Hall et al., 1981). This has led to our current view that recruitment and functional activation of eosinophils, basophils, and mononuclear cells in the airway mucosa play a key role in protective immunity as well as in the development of virus-associated wheezing during naturally acquired RSV infection. Active research during the past 5 years has led to the discovery of a number of cytokines, chemokines, and CSFs that are produced in vitro by virus-infected respiratory epithelial cells in both cell lines and primary cultures (Table 83.3). IL-8 was the first cytokine that was demonstrated in the supernatant of influenza- and RSV-infected nasal, bronchial, and lung type II epithelial cells. Synthesis of IL-8 appears to be dose and time dependent, to require replicating virus, and to be primarily transcriptionally induced (Arnold et al., 1994; Garofalo, et al., 1996a). Concurrently with the discovery of IL-8, a number of different laboratories have reported the presence of IL-6 in the supernatant of airway epithelial cells infected by RSV, rhinovirus, and influenza virus (Table 83.3). The mechanism of IL-6 production in RSV-infected lung epithelial cells appears to be regulated by the autocrine release of IL-1α and, to less extent, IL-1β and TNF-α (Jiang et al., 1998), cytokines with potent bioactivity in infected epithelial cell supernatant. In this regard, IL-1α has been shown to enhance the expression of the intercellular adhesion molecule-1 (ICAM-1) on infected pulmonary epithelial cells (Patel et al., 1995).
Moreover, we have demonstrated that RSV infection elicits interferon-β (IFN-β) production by a number of respiratory epithelial cells, which in turn leads to an increase in their synthesis of class I MHC molecules (Garofalo et al., 1996b). Because mice infected with RSV develop a lymphocytosis in the bronchoalveolar lavage (BAL) fluid, which is predominantly CD8+ T cells (Kimpen et al., 1992; Openshaw, 1989), and adoptive transfer of CD8+ CTL causes hemorrhagic pneumonitis (Cannon et al., 1988), the increased expression of class I MHC by respiratory epithelial cells during RSV infection marks the infected cells, and possibly neighboring cells that passively acquire released RSV peptides, for CTL-mediated lysis and associated immunopathology. Thus, increased expression of class I MHC mediated by IFN-β and other inflammatory cytokines released in infected airway mucosa may be considered an important component of the immunopathologic response to RSV. However, IFN-β may play an equally important role in the protective immune response to RSV by inhibiting or restricting viral infection (Merolla et al., 1995) and by enhancing expression of class I MHC on the infected cells and their lysis by RSV-specific CTL. IL-11, an IL-6-type cytokine, has been shown to be produced by A549 (type II lung cells) infected with RSV, parainfluenza type 3, and rhinovirus 14 (Einarsson et al., 1996).

A quite impressive list of different pharmaceutical and chemical agents has been shown to modulate in vitro virus-induced cytokine production, including dexamethasone, ribavirin, sodium salicylate, aspirin, dimethyl sulfoxide, and amiloride (Jiang et al., 1998; Bitko et al., 1997; Mastronarde et al., 1995, 1996a). Although the effect of some of these compounds on virus-induced cytokine may be due to their well-known antiviral or generically anti-inflammatory properties, the exact mechanism of activity of most of the other compounds used in those studies is poorly understood.

We have investigated the expression and release of the CC chemokines RANTES, MCP-1, and MIP-1α in response to RSV in primary cultures of human nose- and adenoid-derived epithelial cells, epithelial cells derived from the large bronchi (NHBE) or from the terminal bronchioles (SAE), and A549 cells, using (RT-PCR), Northern blot and specific ELISA. The profile and concentrations of the CC chemokines produced by the respiratory epithelium were

| Cytokines          | Viral Agents | References                                                                 |
|--------------------|--------------|----------------------------------------------------------------------------|
| **Inflammatory cytokines** |              |                                                                            |
| IL-1α, IL-β, TNF-α | RSV          | Patel et al. (1995)                                                        |
| IL-6               | RSV, rhinovirus, influenza | Noah and Becker (1993), Arnold et al. (1994), Jiang et al. (1998), Subauste et al. (1995), Zhu et al. (1996), Matsukura et al. (1996) |
| IL-11              | RSV, rhinovirus, parainfluenza | Einarsson et al. (1996), Bitko et al. (1997)                               |
| IFN-β              | RSV          | Garofalo et al. (1996b)                                                    |
| **CXC chemokines** |              |                                                                            |
| GRO-α              | RSV          | Garofalo and Ogra (1996)                                                   |
| IL-8               | RSV, rhinovirus, influenza | Noah and Becker (1993), Becker et al. (1993), Arnold et al. (1994), Mastronarde et al. (1995), Fielder et al. (1995), Garofalo et al. (1995), Garofalo et al. (1996a), Subauste (1995), Choi and Jacoby (1992), Matsukura et al. (1996) |
| **CC chemokines** |              |                                                                            |
| MCP-1              | RSV          | Garofalo and Ogra (1996), Olszkowska-Pazdrak et al. (1998a)                 |
| MIP-1α             | RSV          | Garofalo and Ogra (1996), Olszkowska-Pazdrak et al. (1998a)                 |
| RANTES             | RSV, influenza | Garofalo and Ogra (1996), Saito et al. (1997), Becker et al. (1997), Olszkowska-Pazdrak et al. (1998a), Matsukura et al. (1996) |
| **Colony-stimulating factors** |              |                                                                            |
| G-CSF              | RSV          | Garofalo and Ogra (1996)                                                   |
| GM-CSF             | RSV, rhinovirus | Noah et al. (1993), Garofalo and Ogra (1996), Subauste et al. (1995)    |
characteristically cell specific. RSV infection induced the release of RANTES by epithelial cells isolated from the upper respiratory airways (Saito et al., 1997) and from all the segments of the lower respiratory tract (Garofalo and Ogra, 1996; Olszewska-Pazdrak et al., 1998a). Similar findings using a bronchial cell line have been reported by another group (Becker et al., 1997). With regard to the protein concentration, RSV-infected epithelial cells obtained from the distal portion of the bronchial tree (SAE) and type II cells (A549) produced significantly greater levels of RANTES than those from the major bronchi and the upper airways. In contrast to the widespread expression of RANTES in the infected respiratory epithelium, RSV induced the release of MCP-1 only from A549 cells. Furthermore, our results demonstrate for the first time that when infected human epithelial cells, both the A549 cell line and the normal SAE cells, are able to express and secrete MIP-1α (Fig. 83.1). Thus, the release of MCP-1 and MIP-1α by the airway epithelial cells appears to be regionalized in the distal segments of the bronchial tree and in the lung, a site where RSV-mediated necrosis of the epithelium and peribronchial cellular infiltration are associated with greater pathologic changes, particularly in infected young infants. Moreover, because the recently discovered CC chemokine eotaxin appears to be a potent and specific chemoattractant for eosinophils and Th2 cells, we investigated by Northern blot the expression of eotaxin mRNA in RSV-infected A549 cells. As shown in Figure 83.2, RSV infection of A549 cells induced the accumulation of eotaxin mRNA with maximal accumulation at 36 hours postinfection (R.P. Garofalo, personal communication, 1998). With regard to other cytokines with known activity on eosinophils, it is of interest that both RSV and rhinovirus appear to be strong inducers of GM-CSF by bronchial and lung epithelial cells (Noah and Becker, 1993; Garofalo and Ogra, 1996; Subauste et al., 1995). These findings have important implications for the activation and enhanced survival of human eosinophils in the airway mucosa.

Epithelial cytokines and respiratory viruses (in vivo)

Still limited are the human studies that have appeared in the literature addressing the presence, concentration, and clinical correlate of cytokines in biologic samples of subjects with respiratory viral infections. Increased levels of IL-1 have been measured in nasal secretions of volunteers during experimental rhinovirus colds (Proud et al., 1994). IL-6 has been detected in the respiratory secretions and middle ear effusions during naturally acquired RSV infection (Matsuda et al., 1995; Noah et al., 1995; Okamoto et al., 1993) and in experimental infection with rhinovirus (Zhu et al., 1996). IL-8 has been demonstrated in nasal lavage fluids of children with upper viral infections (Noah et al., 1995) and in middle ear effusions of children with antigen-proven viral otitis media (Chonmaitree et al., 1996). mRNA for IL-1β and TNF-α have also been found in middle ear effusions positive for RSV genome (Okamoto et al., 1993). In addition, IL-11 can be detected in vivo during viral upper respiratory infections (Einarsson et al., 1996). Levels of IL-6,
II-8, TNF-α, and IL-1β appear to be high in nasal washes of children with RSV lower respiratory tract disease and decrease during convalescence (Neuzil and Graham, 1996). High amounts of the CC chemokines RANTES and MIP-1α have been demonstrated in the nasopharyngeal secretions of infants with different forms of RSV respiratory disease (Becker et al., 1997; R.P. Garofalo and R.C. Welliver, personal communication, 1998).

Transcriptional activation of epithelial cytokines by respiratory viruses

Inducible genes such as those that encode for cytokines, chemokines, and CSFs are regulated by transcription factors that are activated by diversified extracellular stimuli and bind to the promoter region of the genes to increase their rate of transcription. Although many transcription factors have been identified and are involved in the regulation of these genes, two, nuclear factor (NF) NF-IL-6 and NF-κB, appear to be of particular importance. The identification of factors that control switches in epithelial cells is central to the understanding of virus-host interaction.

NF-IL-6, a human basic domain-leucine zipper-containing transcription factor, is an important transcription factor participating in inducible gene expression in acute infectious and inflammatory responses (Akira et al., 1990; Brasier and Kumar, 1994). Originally identified as a transcription factor that bound to the inducible enhancer of the IL-6 gene, NF-IL6 has been shown to promote the activity of other genes, including IL-8 and GM-CSF (Dunn et al., 1994; Stein and Baldwin, 1993) and acute-phase reactants angiotensinogen and serum amyloid A (Akira et al., 1990). The expression of NF-IL-6 is controlled in a tissue-type-dependent fashion. In the many tissues that express NF-IL-6 mRNA, such as the liver and brain, the protein is also produced. In the lung, however, a discrepancy has been noted (Descombes et al., 1990). Although normal lung tissue is, in fact, one of the most productive sources of NF-IL-6 mRNA, the NF-IL-6 protein is almost undetectable. This observation suggests that tissue-specific factors are involved in the control of posttranscriptional expression of NF-IL-6. However, data from Brasier’s group indicate that human alveolar type II epithelial cells synthesize the NF-IL-6 transcription factor in response to RSV replication (Jamaluddin et al., 1996). RSV infection stimulates the translational synthesis of a single NF-IL-6 isoform comigrating with recombinant NF-IL-6 (amino acids 24 to 345). The induction of NF-IL-6 is independent of changes in NF-IL-6 mRNA and is associated with an increased rate of NF-IL-6 synthesis. Thus, the accumulation of NF-IL-6 after RSV infection is due to increased translation of the preformed NF-IL-6 mRNA. The mechanisms for enhanced translation of preformed mRNA used by RSV are contrasted with an effect of influenza virus infection in HeLa cells (Wada et al., 1995). Influenza virus infection increased, rapidly and transiently (over 2–4 hours), the DNA-binding activity of preformed NF-IL-6 protein without changing its steady-state levels. That this effect could be reproduced by double-stranded RNA left the suggestion that double-stranded RNA kinase could be an important virus-inducible activator for posttranslational activation of NF-IL-6 DNA-binding activity. Thus, NF-IL-6 activity appears to be inducible by several distinct posttranslational mechanisms by viral infection within the same epithelial cell type.

NF-κB is an inducible transcriptional activator implicated in the inducible expression of viral, cytokine, and acute-phase reactant genes by binding to regulatory sites within the promoters of these genes (reviewed in Baeuerle [1991] and Thanos and Maniatis [1995]). Of relevance to pulmonary inflammation, NF-κB activates the expression of IL-8, and many other inflammatory gene products, such as IL-6, IL-11, GM-CSF, TNF-α, and ICAM-1, whose expression is known to be enhanced by RSV infection (see Table 83.3 and Patel et al., [1995]). Therefore, NF-κB activation may be responsible for activating gene networks of inflammatory molecules and cell surface receptors required for immune activation in the bronchial mucosa.

As shown previously (Table 83.3), in vitro studies have shown a dramatic production of IL-8 by airway epithelial cells on RSV infection through an incompletely characterized mechanism involving enhanced gene expression. Thus, using the model of lung type II alveolar epithelial cells (A549) to study the initial events in viral-induced regulation of gene expression, we have investigated the mechanism for IL-8 induction by RSV infection. Infection with sucrose purified RSV produced a time-dependent increase in transcriptional initiation rate of the IL-8 gene. Transient transcription of the human IL-8 promoter mutated in the binding site for NF-κB demonstrated that this sequence is essential for RSV-activated transcription (Garofalo et al., 1996a). Gel mobility shift assays (EMSA) demonstrated RSV induction of sequence-specific NF-κB binding complexes. NF-κB is a transcription factor superfamily composed of NF-κB1, NF-κB2, Rel A, and c-Rel proteins that heterodimerize in cells expressing them, producing complexes with various transcriptional activity and subtle sequence-specific binding preferences. For this reason, we also tested whether the inducible complexes cross-reacted with specific antibodies for various NF-κB subunits in the EMSA. These complexes were supershifted only by antibodies directed to the potent transactivating subunit Rel A. Both Western immunoblot and indirect immunofluorescence assays showed that cytoplasmic Rel A in uninfected cells localized to the nucleus after RSV infection. Rel A activation requires replicating RSV because neither viral conditioned medium nor UV-inactivated RSV were able to stimulate its translocation. Other laboratories have demonstrated an increase in NF-κB DNA-binding activity following RSV infection (Bitko et al., 1997; Fielder et al., 1996; Mastronarde et al., 1996b), and a simultaneous increase in the nuclear abundance of the potent transcriptional activator RelA (Bitko et al., 1997). This event appears to be essential not only for IL-8 but also for the activity of a genetic network including the cytokines IL-1, IL-6, and IL-11 in RSV-infected epithelium (Bitko et al., 1997). Moreover, NF-κB activation has been reported as a
consequence of Sendai virus infection of fibroblastic and renal carcinoma cells (Garofalis et al., 1994) and rhinovirus infection of alveolar epithelial cells (Zhu et al., 1996). The kinetics of Rel A activation in response to RSV infection occurs slowly, requiring 3–12 hours before significantly detectable NF-κB protein can accumulate in the nucleus (Garofalo et al., 1996a). This contrasts with an extremely rapid NF-κB activation in response to hormone receptors (such as TNF-α) where NF-κB is activated within minutes and the intermediate activation observed during rhinovirus infection (Zhu et al., 1996). Other investigators, using non-purified viral preparations, have shown a biphasic effect for NF-κB activation (Fielder et al., 1996; Mastronarde et al., 1996b), where an initial transient, replication-independent increase in NF-κB binding is seen 30–90 minutes postinfection, followed by a nadir and a gradual reaccumulation after 24 hours. These differences in NF-κB kinetics, as well as in the pattern of cytokine and other inflammatory gene expression, may be due to the contamination of the nonpurified viral preparations with NF-κB activating cytokine activity such as IL-1, known to be produced by human epithelial cells routinely used for RSV and other respiratory virus growth. Our observations imply that although NF-κB activation may be a final common pathway for both infectious and inflammatory signaling, this event is mediated by distinct intracellular signaling mechanisms. During RSV infection, we note that the kinetics of Rel A activation coincide with the production of viral antigens. This time course and the observation that both NF-κB and IL-8 production do not occur in response to exposure to RSV-conditioned medium or to UV-inactivated virus argues that the process of active viral replication may be necessary to trigger NF-κB binding and subsequent IL-8 synthesis. Indeed, viral products of replication such as free radicals (Schreck et al., 1991) and double-stranded RNA (Visvanathan and Goodbourn, 1989) are potent activators of NF-κB in certain cell types. It is interesting to speculate that the expression of one or more viral gene products may be responsible for activating Rel A translocation (Fig. 83.3).

Inducible NF-κB subunits interact with cytoplasmic inhibitors, collectively known as IκBs, through motifs contained within a conserved NH2-terminal Rel homology domain. IκB subunits, responsible for cytoplasmic retention and inactivation of NF-κB DNA-binding activity, consist predominantly of four isoforms, IκBα, IκBβ, IκBγ, and the NF-κB1 precursor that are expressed and regulated in a cell-specific fashion (Beg and Baldwin, 1993). NF-κB-inducing signals control its cytoplasmic-nuclear abundance by a mechanism involving proteolytic degradation of the IκB inhibitor. Once liberated, free cytoplasmic NF-κB passes through the nuclear pore complex and enters the nucleus to bind and activate target genes. Stimulation of cells with TNF-α results in rapid serine phosphorylation of the IκBα NH2 terminus, an event coupled to the rapid polyubiquitination and proteolysis of phospho-IκB through the 26S proteasome (DiDonato et al., 1996). Brasier’s group has

![Fig. 83.3.](image-url)

Infection of alveolar type II epithelial cells by RSV results in the rapid synthesis (within 3 hours) of NF-IL6, a basic domain-leucine zipper-containing transcription factor. In addition, RSV infection results in the activation of NF-κB (i.e., Rel A DNA binding) that begins at 3 hours and peaks at 24 hours and that involves proteolysis of the IκBα inhibitor via a still unknown and (largely) proteasome-independent pathway. Cytoplasmic-nuclear translocation of RelA and binding of RelA and NF-IL6 to regulatory consensus sites within the promoters of cytokine, adhesion molecules, or other inflammatory genes are responsible for their transcription. The role of specific RSV protein in the translational regulation of NF-IL-6 and in the activation of NF-κB is currently unknown. vRNA, viral RNA; 1C, 1B, N, P, M, 1A, G, F, 22K, L identify the 10 RSV proteins.
systematically investigated the mechanism and kinetics of NF-xB activation in RSV-infected airway epithelial cells in comparison to TNF-a (Jamaluddin et al., 1998). In contrast to the rapid activation of Rel A produced by TNF-α, RSV infection produces a gradual increase in Rel A binding peaking at 24 hours. For both activators TNF-α and RSV, IκBα and IκBβ proteolysis occurred in parallel with the increases in Rel A DNA-binding activity. Specific proteasome inhibitors lactacystin, MG-132, and ZLLF-CHO significantly blocked 26S protease activity and IκBα proteolysis induced by TNF-α. However, although total proteasome activity in RSV-infected cells increased by twofold and its activity was almost completely inhibited by the proteasome inhibitors, they did not prevent IκBα proteolysis by RSV infection. These data indicate a major component of IκBα proteolysis occurs via a proteasome-independent mechanism in viral-infected epithelium.

**SUMMARY**

RSV, the most common etiologic agent worldwide to induce lower respiratory tract infections in infants and young children, has been linked to the development of asthma, airway hyperresponsiveness, and sensitization to environmental allergens. The mechanisms of RSV-induced airway disease and its the long-term consequences are largely unknown, but the delicate balance between immunopathology and immunoprotection in the airway mucosa may be altered by an exuberant and unwanted local inflammatory response. Massive infiltration of mononuclear cells and activation of eosinophil and basophil leukocytes has been shown to correlate with the severity of acute RSV disease in both human and animal models. Inflammatory cytokines and CC chemokines with discrete target-cell selectivity for eosinophils and Th2 cells are strongly induced to express in RSV-infected respiratory epithelium. We propose a cohesive hypothesis that links RSV, and perhaps other respiratory viral infections, to the development of respiratory allergic disease, in which the inducible production of CC chemokines by RSV is regulated by intracellular pathways and signaling mechanisms characterized by the increased rate of NF-IL-6 synthesis, cytoplasmic-nuclear translocation of the potent transcription factor NF-xB leading to the transcriptional induction of CC chemokine genes. The secretion of CC chemokines, including RANTES and eotaxin by respiratory epithelial cells, in combination with Th2-derived cytokines, is the central pathogenetic event in airway mucosa inflammation, sensitization to bystander antigens, and augmentation of allergen-induced Th2 cell recruitment. Moreover, pattern and absolute levels as well as relative concentrations, together with the kinetics of release of epithelial cell chemokines in different areas of the respiratory tract, are all factors that may significantly contribute to the various histologic and inflammatory features of RSV-induced airway disease. Selective production of MIP-1α, MCP-1, and the severalfold higher amount of RANTES released by epithelial cells of the small bronchioles and lung in comparison to bronchial or upper airway epithelium, along with autocrine and paracrine mechanisms of amplification may largely explain the findings of mononuclear cell infiltration, eosinophil and basophil migration, and activation. Future studies, both in children with different forms of RSV-induced airway disease and in animal models, are needed to correlate the different parameters of histopathology, inflammation, and immune response with the expression and secretion of cytokines, chemokines, and CSFs in airway mucosa.

**ACKNOWLEDGMENTS**

We thank the current and former fellows of Drs. Brasier’s, Garofalo’s and Patel’s laboratories, including Antonella Casola, Barbara Olszewska-Pazdruk, Mohammad Jamaluddin, Zili Jiang, Masaru Kunimoto, Monica Manganaro, Mona Sabry, and Tadahito Saito, who greatly contributed to the published and unpublished work discussed in this chapter. We greatly appreciate the help of Judith Maurino and Virginia Reimer in the preparation of this publication. This work was supported in parts by grants A115939 and A140218, from the National Institutes of Health.

**REFERENCES**

Aberle, J. H., Aberle, S. W., Dworzak, N., Mandl, C. W., Rebhandl, W., Vollnhofer, G., Kundi, M., and Popow-Kraupp, T. (1999). Reduced interferon-γ expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. *Am. J. Respir. Crit. Care Med.* 160, 1263–1268.

Adachi, M., Matsuura, S., Tokunaga, H., and Kobata, F. (1997). Expression of cytokines on human bronchial epithelial cells induced by influenza virus A. *Int. Arch. Allergy Immunol.* 113, 307–311.

Aherne, W., Bird, T., Court, S. D. M., Gardner, P. S. and McQuillin, J. (1970). Pathologic changes in virus infections of the lower respiratory tract in children. *J. Clin. Pathol.* 23, 7–18.

Akira, S., Iishika, H., Sugita, T., Tanabe, O., Kinoshita, S., Nishio, Y., Nakajima, T., Hirano, T., and Kishimoto, T. (1990). A nuclear factor for IL-6 expression (NF-IL-6) is a member of a C/EBP family. *EMBO J.* 9, 1897–1906.

Anderson, L. J., Tsou, C., Potter, C., Keyserling, H. L., Smith, T. F., Ananaba, G. and Bangham C. R. M. (1994). Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells. *J. Infect. Dis.* 170, 1201–1208.

Arai, K., Lee, F., Miyajima, A., Miyatake, S., Arai, N. and Yokota, T. (1990). Cytokines: Coordinators of immune and inflammatory responses. *Annu. Rev. Biochem.* 59, 783–836.

Arnold, R., Humbert, B., Werchau, H., Gallati, H. and Koning, W. (1994). Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. *Immunology* 82, 126–133.

Baeuerle, P. A. (1991). The inducible transcription activator NF-kappa B: Regulation by distinct protein subunits. *Biochim. Biophys. Acta.* 1072, 63–80.

Baggiolini, M., Dewald, B. and Moser, B. (1997). Human chemokines: An update. *Annu. Rev. Immunol.* 15, 675–705.

Barclay, W. S., al Nakiib, W., Higgins, P. G. and Tyrrell, D. A. (1989). The time course of the humoral immune response to rhinovirus infection. *Epidemiol. Infect.* 103, 659–669.
Becker, S., Koren, H. S. and Henke, D. C. (1993). Interleukin-8 expression in normal nasal epithelium and its modulation by infection with respiratory syncytial virus and cytomegalovirus necrosis factor, interleukin-1, and interleukin-6. *Am. J. Respir. Cell Mol. Biol.* 8, 20–27.

Becker, S., Reed, W., Henderson, F. W. and Noah, T. L. (1997). RSV infection of human airway epithelial cells causes production of the β-chemokine RANTES. *Am. J. Physiol.* 272, L512–L520.

Beg, A. A. and Baldwin, A. S., Jr. (1993). The IkB proteins: Multifunctional regulators of Rel/NF-κB transcription factors. *Genes Dev.* 7, 2060–2070.

Bitko, V., Velazquez, A., Yang, L., Yang, Y. and Barik, S. (1997). Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-κB and is inhibited by sodium salicylate and aspirin. *Virology* 232, 369–378.

Bont, L., Heijnen, C. J., Kavelaars, A., van Alderen W. M. C., Brus, F., Draaisma J. M. T., Pekelharing-Berghuis, M., van Diemen-Steenvoorde, R. A. A. M. and Kimpener J. L. L. (2001). Local interferon-γ levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. *J. Infect. Dis.* 184, 355–358.

Boushley, H. A., Holtzmann, M. J., Sheller, J. R. and Nadel, J. A. (1980). β-B proteins: *J. Virol.* 272, 121–131.

Brasier, A. R. and Kumar, A. (1994). Identification of a novel determinant of the 5′ flanking region of the interferon-α promoter. *EMBO J.* 9, 3933–3944.

Brandt, C. D., Kim, H. W., Arrobio, J. O., Jeffries, B. C., Wood, S. C., Bui, R. H. D., Molinaro, G. A., Kittering, J. D., Heiner, D. C., Imagawa, T., Becker, S., Reed, W., Henderson, F. W. and Noah, T. L. (1997). RSV infection of human airway epithelial cells causes production of the β-chemokine RANTES. *Am. J. Physiol.* 272, L512–L520.

Bont, L., Heijnen, C. J., Kavelaars, A., van Alderen W. M. C., Brus, F., Draaisma J. M. T., Pekelharing-Berghuis, M., van Diemen-Steenvoorde, R. A. A. M. and Kimpener J. L. L. (2001). Local interferon-γ levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. *J. Infect. Dis.* 184, 355–358.

Boushley, H. A., Holtzmann, M. J., Sheller, J. R. and Nadel, J. A. (1980). β-B proteins: *J. Virol.* 272, 121–131.

Brasier, A. R. and Kumar, A. (1994). Identification of a novel determinant of the 5′ flanking region of the interferon-α promoter. *EMBO J.* 9, 3933–3944.

Bui, R. H. D., Molinaro, G. A., Kittering, J. D., Heiner, D. C., Imagawa, T. D. and St. Geme, J. W., Jr. (1987). Virus-specific IgE and IgG4 antibodies in serum and nasal wash antibodies associated with resistance to respiratory syncytial virus disease in Korean children. *J. Allergy Clin. Immunology* 77, 330–337.

Bont, L., Heijnen, C. J., Kavelaars, A., van Alderen W. M. C., Brus, F., Draaisma J. M. T., Pekelharing-Berghuis, M., van Diemen-Steenvoorde, R. A. A. M. and Kimpener J. L. L. (2001). Local interferon-γ levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. *J. Infect. Dis.* 184, 355–358.

Colombo Zelaya, E. A., Orvell, C. and Strannegard, O. (1994). Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus. *Pediatr. Allergy Immunol.* 5, 300–305.

Cook, D. N., Beck, M. A., Coffman, T. M., Kirby, S. L., Sheridan, J. F., Pragnell, I. B. and Smithies, O. (1995). Requirement of MIP-1α for an inflammatory response to viral infection. *Science* 269, 1583–1585.

Corne, J. M. and Holgate, S. T. (1997). Mechanisms of virus induced exacerbations of asthma. *Thorax* 52, 380–389.

Cromwell, O., Hamid, Q., Corrigan, C. J., Barkans, J., Meng, Q. and Collins, P. D. (1992). Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1β and tumour necrosis factor-α. *Immunology* 77, 330–337.

de Arruda, E., III, Mifflin, T. E., Gwaltney, J. M., Jr., Winther, B. and Hayden, F. G. (1991). Localization of rhinovirus replication in vivo with in situ hybridization. *J. Med. Virol.* 34, 38–44.

Denny, F. W. and Clyde, W. A., Jr. (1986). Acute lower respiratory tract infections in nonhospitalized children. *J. Pediatr.* 108, 635–646.

Descombes, P., Chojkier, M., Lichteinstein, S., Falvey, E. and Schibler, U. (1990). LAP, a novel member of the c/ebp gene family, encodes a liver enriched transcriptional activator protein. *Genes Dev.* 4, 1541–1551.

DiDonato, J., Mercurio, F., Rosette, C., Wa-Li, J., Suyang, H., Ghosh, S. and Karin, M. (1996). Mapping of the inducible iKB phosphorylation sites that signal its ubiquitination and degradation. *Mol. Cell. Biol.* 16, 1295–1304.

Dinarello, C. A. (1992). Role of interleukin-1 in infectious diseases. *Inmunol. Rev.* 127, 119–146.

Dunn, S. M., Coles, S., Lang, R. K., Gerondakis, S., Vadis, M. A. and Shannon, M. F. (1994). Requirement for nuclear factor (NF)-κB p65 and NF-interleukin-6 binding proteins in the tumor necrosis factor responses of the granulocyte colony-stimulating factor. *Proc. Natl. Acad. Sci. U. S. A.* 74, 3006–3010.

Dupont, P., Rietsch, L., Schmitz, S., Falvey, E. and Schibler, U. (1990). LAP, a novel member of the c/ebp gene family, encodes a liver enriched transcriptional activator protein. *Genes Dev.* 4, 1541–1551.

Dunn, S. M., Coles, S., Lang, R. K., Gerondakis, S., Vadis, M. A. and Shannon, M. F. (1994). Requirement for nuclear factor (NF)-κB p65 and NF-interleukin-6 binding proteins in the tumor necrosis factor responses of the granulocyte colony-stimulating factor. *Proc. Natl. Acad. Sci. U. S. A.* 74, 3006–3010.

Empey, D. W., Laitinen, L. A., Jacobs, L., Gold, W. M. and Nadel, J. A. (1976). Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. *Am. Rev. Respir. Dis.* 113, 131–138.

Ennis, F. A., Martin, W. J. and Verbonitz, M. W. (1977). Specificity studies on cytotoxic thymus-derived lymphocytes reactive with influenza virus infected cells: Evidence for dual recognition of H2 and the viral hemagglutinin antigens. *Proc. Natl. Acad. Sci. U. S. A.* 74, 2469–2479.

Ennis, F. A., Maeger, A., Beare, S., Yi-Hua, Q., Reilly, B., Schwarz, G., Schild, G. C. and Rook, A. H. (1981). Interferon induction in increased natural killer cell activity in influenza infections in man. *Lancet* 2, 891–895.

Fielder, M. A., Wernke-Dollries, K., and Stark, J. M. (1995). Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. *Lung Cell Mol. Pathiol.* 13, L865–L872.

Fielder, M. A., Wernke-Dollries, K., and Stark, J. M. (1996). Inhibition of viral replication reverses respiratory syncytial virus-induced NF-κB activation and interleukin-8 gene expression in A549 cells. *J. Virol.* 70, 9079–9082.

Fishman, M., Tubergen, D. and McNtosh, K. (1980). Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. *J. Pediatr.* 96, 179–186.

Fleischer, B., Biehl, H. and Rott, R. (1985). Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. *J. Immunol.* 135, 2808–2804.

Fox, J. P., Cooney, M. K., Hall, G. E. and Foy, H. M. (1985). Rhinoviruses in Seattle families, 1975–1979. *Am. J. Epidemiol.* 122, 830–846.

Fraenkel, D. J., Bardin, P. G., Sanderson, G., Lampe, F., Johnston, S. L. and Holgate, S. T. (1994). Immunohistochemical analysis of nasal biopsies during rhinovirus experimental colds. *Am. J. Respir. Crit. Care Med.* 150, 1130–1136.
Chapter 83  Clinical Aspects of Bronchial Reactivity and Cell–Virus Interaction

Fraenkel, D. J., Bardin, P. G., Sanderson, G., Lampe, F., Johnston, S. L. and Holgate, S. T. (1995). Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am. J. Respir. Crit. Care Med. 151, 879–886.

Frank, A. L., Taber, L. H., Glezen, W. P., Paraske, A. and Couch, R. B. (1979). Reinfection with influenza A (H3N2) virus in young children and their families. J. Infect. Dis. 140, 829–836.

Frechorst, J., Piedra, P. A., Okamoto, Y. and Ogra, P. L. (1988). Effect of respiratory syncytial virus infection on the uptake of and immune response to other inhaled antigens. Proc. Soc. Exp. Biol. Med. 188, 181–187.

Fryer, A. D., Jacoby, D. B. and Djokic, T. D. (1991). Parainfluenza virus responsiveness in allergic subjects. Am. J. Dis. Child. 155, 609–616.

Garofalo, R., Mei, F., Espejo, R., Ye, G., Haeberle, H., Baron, S., Ogra, P. L. and Reyes, V. E. (1996). Respiratory syncytial virus infection of human respiratory epithelial cells upregulates Class I MHC expression through the induction of IFN-β and IL-10. J. Immunol. 157, 2506–2513.

Garofalo, R. and Ogra, P. L. (1996). Mechanisms of mucosal immunopathology in respiratory syncytial virus infection. In Mucosal Immunology (eds. M. F. Kagnoff and H. Kiyono), pp. 405–420. San Diego: Academic Press.

Garofalo, R., Sabry, M., Jamaluddin, M., Yu, R. K., Casola, A., Ogra, P. L. and Brasier, A. R. (1996a). Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: Nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal inflammation. J. Virol. 70, 8773–8781.

Garofalo, R., Welliver, R. C. and Ogra, P. L. (1991). Concentrations of LTβ, LTβ, and LTα, in bronchial secretions due to respiratory syncytial virus. Pediatr. Allergy Immunol. 2, 30–37.

Garofalo, R. P., Patti, J., Hintz, K. A., Hill, V., Ogra, P. L. and Welliver, R. C. (2001). Macrophage inflammatory protein-1α (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis. 184, 393–399.

Garoufalis, E., Kwan, I., Lin, A., Mustafa, N., Pepin, A., Roulston, J., Garofalo, R., Welliver, R. C. and Ogra, P. L. and Reyes, V. E. (1996b). Respiratory syncytial virus infection of human pulmonary epithelial cells infected with respiratory syncytial virus with interleukin-4 and interleukin-4 receptor α polymorphisms. J. Infect. Dis. 187, 2–11.

Heynes, J. L. and Tauber, A. I. (1995). The influenza virus-infected phagocyte: A model of deactivation. Harben/Oscl. Clin. N. Am. 2, 301–315.

Hayes, P. J., Scott, R. and Wheeler, J. (1994). In vivo production of tumor necrosis factor-alpha and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J. Med. Virol. 42, 323–329.

Helperin, S. A., Eggleston, P. A., Hendley, J. O., Suratt, P. M., Groschel, D. H. M. and Gwaltney, J. M., Jr. (1983). Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. Am. Rev. Respir. Dis. 128, 806–810.

Hoebe, B., Rietveld, E., Bont, L., van Ooster, M., Hodemakers, H. M., Nagelkerke, N. J. D., Neijens, H. J., Kimpen, J. L. and Kimman, T. G. (2003). Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor α polymorphisms. J. Infect. Dis. 151, 879–886.

Heymann, P. W. (1995). Eosinophil cationic protein in serum and airway secrections in asthmatic subjects. J. Allergy Clin. Immunol. 95, 2–11.

Ingram, J. M., Rakes, G. P., Hooyer, G. E., Platts-Mills, T. A. E. and Holgate, S. T. (1995). Lower airways inflammation during naturally acquired respiratory syncytial virus infection. Pediatr. Allergy Immunol. 5, 111–117.

Kahler, C., Bock, L., Thuerey, N., Oldenburg, B., Bode, H., Krohn, M., Koschinsky, T., Ritzel, R., Blume, G. and von der Adler, E. (1996). The major component of IκBα is also present in IIκBα and can be released from NF-κB-containing immune cells in vitro. J. Immunol. 157, 2506–2513.

Kahler, C. and Holgate, S. T. (1995). Eosinophilic infiltration of the lower airways in asthma. J. Allergy Clin. Immunol. 95, 2–11.

Lee, S. Y., Park, Y. D., Lee, J. Y., Lee, H. C., Kim, S. K., Kang, S. Y., Kim, K. H., Lim, S. H. and Han, D. J. (1997). Effect of inhaled corticosteroids on the expression of IL-6 in patients with chronic obstructive pulmonary disease. Chest 112, 319–325.

Lee, S. Y., Park, Y. D., Lee, J. Y., Lee, H. C., Kim, S. K., Kang, S. Y., Kim, K. H., Lim, S. H. and Han, D. J. (1997). Effect of inhaled corticosteroids on the expression of IL-6 in patients with chronic obstructive pulmonary disease. Chest 112, 319–325.

Lee, S. Y., Park, Y. D., Lee, J. Y., Lee, H. C., Kim, S. K., Kang, S. Y., Kim, K. H., Lim, S. H. and Han, D. J. (1997). Effect of inhaled corticosteroids on the expression of IL-6 in patients with chronic obstructive pulmonary disease. Chest 112, 319–325.

Lee, S. Y., Park, Y. D., Lee, J. Y., Lee, H. C., Kim, S. K., Kang, S. Y., Kim, K. H., Lim, S. H. and Han, D. J. (1997). Effect of inhaled corticosteroids on the expression of IL-6 in patients with chronic obstructive pulmonary disease. Chest 112, 319–325.
activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus. Clin. Diag. Lab. Immunol. 2, 322–324.

Matsukura, S., Kokubu, F., Noda, H., Tokunaga, H., Kadokura, M., Yamamoto, T., Kuroiwa, Y., Ohno, T., Suzaki, H. and Adachi, M. (1998). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.

Matsukura, S., Kokubu, F., Noda, H., Tokunaga, H. and Adachi, M. (1996). Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells. Arch. Virol. Suppl. 5, 183–187.

Matsukura, S., Kokubu, F., Kubo, H., Tomita, T., Tokunaga, H., Kadokura, M., Yamamoto, T., Kuroiwa, Y., Ohno, T., Suzaki, H. and Adachi, M. (1998). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.

Nadal, J. A. (1991). Neutrophil elastase and secretory component of excessive lower respiratory tract epithelial cells. J. Infect. Dis. 163, 137–142.

Nadal, J. A. (1991). Neutrophil elastase and secretory component of excessive lower respiratory tract epithelial cells. J. Infect. Dis. 163, 137–142.

Nakagawa, Y. K., Ishikawa, K., Ito, E., Togawa, K., Patel, J. A. and Ogra, P. L. (1999). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.

Nakamura, M., Nakamura, M., Kurosaka, M., Kurosawa, M., Uchiyama, M. and Adachi, M. (1998). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.

Naclerio, R. M., Proud, D., Lichtenstein, L. M., Kagey-Sobotka, A., Hendley, J. O., Sorrentino, J. and Gwaltney, J. M. (1988). Kinins are generated during experimental rhinovirus colds. J. Infect. Dis. 157, 133–142.

Naclerio, R. M., Proud, D., Lichtenstein, L. M., Kagey-Sobotka, A., Hendley, J. O., Sorrentino, J. and Gwaltney, J. M. (1988). Kinins are generated during experimental rhinovirus colds. J. Infect. Dis. 157, 133–142.

Neuzil, K. M. and Graham, B. S. (1996). Cytokine release and innate immunity in respiratory viral infection. Semin. Virol. 7, 255–264.

Nicolson, K. G., Kent, J. and Ireland, D. C. (1993). Respiratory viruses and exacerbations of asthma in adults. BMJ 307, 982–986.

Noah, T. L. and Becker, S. (1993). Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line. Am. J. Physiol. 265, L472–L478.

Noah, T. L., Henderson, F. W., Wortman, I. A., Devlin, R. B., Handy, J., Loren, H. S., and Becker, S. (1995). Nasal cytokine production in viral acute upper respiratory infection of childhood. J. Infect. Dis. 171, 584–592.

Ogra, P. L., Chow, T. and Beutner, K. R. (1977). Clinical evaluation of respiratory syncytial virus infection in infants and children. J. Infect. Dis. 135, 499–506.

Ohtoshi, T., Vancheri, C., Cox, G., Gauldie, J., Dolovich, J., Denburg, J. A. and Jordana, M. (1991). Monocyte-macrophage differentiation induced by respiratory syncytial virus. J. Infect. Dis. 163, 255–263.

Okamoto, Y. K., Ishikawa, K., Iro, E., Togawa, K., Patel, J. A. and Ogra, P. L. (1993). Presence of respiratory syncytial virus genomic sequences in middle ear fluid and its relationship to expression of cytokines and cell adhesion molecules. J. Infect. Dis. 168, 1277–1281.

Olszewska-Pazdur, B., Casola, A., Saito, T., Alam, R., Crowe, S. E., Mei, F., Ogra, P. L. and Garofalo, R. P. (1998a). Cell-specific expression of RANTES, MCP-1 and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J. Virol. 72, 4756–4764.

Olszewska-Pazdur, B., Pazdur, K., Ogra, P. L. and Garofalo, R. P. (1998a). Cell-specific expression of RANTES, MCP-1 and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J. Virol. 72, 4756–4764.

Olszewska-Pazdur, B., Pazdur, K., Ogra, P. L. and Garofalo, R. P. (1998b). Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. J. Immunol. 160, 4889–4895.

Openshaw, P. J. M. (1989). Flow cytometric analysis of pulmonary lymphocytes from mice infected with respiratory syncytial virus. Clin. Exp. Immunol. 75, 324–328.

Openshaw, P. J. M. (1995). Immunopathological mechanisms in respiratory syncytial virus disease. Springer Semin. Immunol. 17, 187–201.

Oppenheim, J. J., Zachariae, C. O. C., Mukaida, N. and Matsushima, K. (1991). Properties of the novel proinflammatory supergene product ‘intercrine’ cytokine family. Annu. Rev. Immunol. 9, 617–648.

Park, D. E., Busse, W. W., Sukow, K. A., Dick, C. R., Swenson, C. and Gern, J. E. (2000). Rhinovirus-induced PBMC responses and activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus. Clin. Diag. Lab. Immunol. 2, 322–324.

Matsukura, S., Kokubu, F., Noda, H., Tokunaga, H. and Adachi, M. (1998). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.

Matsukura, S., Kokubu, F., Noda, H., Tokunaga, H. and Adachi, M. (1996). Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells. Arch. Virol. Suppl. 5, 183–187.

Matsukura, S., Kokubu, F., Kubo, H., Tomita, T., Tokunaga, H., Kadokura, M., Yamamoto, T., Kuroiwa, Y., Ohno, T., Suzaki, H. and Adachi, M. (1998). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.

Matsukura, S., Kokubu, F., Noda, H., Tokunaga, H. and Adachi, M. (1996). Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells. Arch. Virol. Suppl. 5, 183–187.

Matsukura, S., Kokubu, F., Kubo, H., Tomita, T., Tokunaga, H., Kadokura, M., Yamamoto, T., Kuroiwa, Y., Ohno, T., Suzaki, H. and Adachi, M. (1998). Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell Mol. Biol. 18, 255–264.
outcome of experimental infection in allergic subjects. *J. Allergy Clin. Immunol.* 105, 692–698.

Patel, J. A., Kumamoto, M., Sim, T. C., Garofalo, R., Elliott, T., Baron, S., Rouskas, C., Chomnawar, T., Ogura, P. L., and Schmalstieg, F. (1995). Interleukin-10 mediates the enhanced expression of intercellular adhesion molecule-1 in pulmonary epithelial cells infected with respiratory syncytial virus. *Am. J. Respir. Cell Mol. Biol.* 13, 602–609.

Prince, G. A., Jenson, A. B., Hemming, V. G., Murphy, B. R., Walsh, E. E., Horswood, R. L. and Chanaoc, R. M. (1986). Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats against viral infection. *J. Virol.* 57, 721–728.

Proud, D., Gwaltney, J. M., Jr. and Hendley, J. O. (1994). Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. *J. Infect. Dis.* 169, 1087–1013.

Proud, D., Naclerio, R., Gwaltney, J. and Hendley, J. (1990). Kinins are generated in nasal secretions during natural rhinovirus colds. *J. Infect. Dis.* 161, 120–123.

Rabatic, S., Gagro, A., Giro, F., Rului, M. C., Covacci, M., and Muzzi, L. (1998). Increase in CD3+ T cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus. *J. Infect. Dis.* 175, 32–37.

Riedel, F., Krause, A., Sienczka, W. and Rieger, C. (1996). Parainfluenza 3-virus infection enhances allergic sensitization in the guinea pig. *Clin. Exp. Allergy* 26, 603–609.

Ruef, C. and Coleman, D. L. (1990). Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. *Rev. Infect. Dis.* 12, 41–62.

Russi, C., Delfraro, A., Borthagaray, M. D., Velazquez, B., Garcia-Saitor, T., Deskin, R. W., Haeberle, H., Olzewska-Pazdrak, B., Alam, R., Roga, P. L. and Garofalo, R. (1997). Respiratory syncytial virus infection induces the selective release of RANTES by upper airway epithelial cells. *J. Infect. Dis.* 175, 497–504.

Sallusto, F., Mackay, C. R. and Lanzavecchia, A. (1997). Selective expression of the costatin receptor CCR3 by human γδ T helper 2 cells. *Science* 272, 2005–2007.

Schreck, R., Rieber, P. and Baeuerle, P. A. (1991). Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κappa B transcription factor and HIV-1. *EMBO J.* 10, 2247–2258.

Schrum, S., Probst, P., Fleischer, B. and Zipfel, P. F. (1996). Synthesis of the CC-chemokines MIP-1α, MIP-1β and RANTES is associated with a type 1 immune response. *J. Immunol.* 157, 3598–3604.

Schwarze, J., Hamelmann, E., Bradley, K. L., Katsu, T. and Gelfand, E. W. (1997). Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitivity to allergen. *J. Clin. Invest.* 100, 226–233.

Sheehan, P., Ji, G., Carubelli, C., Saavedra, J., Johnson, C., Krisher, K., Sanchez, J. P. and Ramilo, O. (1998). Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. *Pediatr. Infect. Dis.* 17, 115–122.

Sigurs, N., Bjarnason, R. and Sigurbergsson, F. (1994). Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus. *Acta Paediatr.* 83, 1151–1155.

Sigurs, N., Bjarnason, R., Sigurbergsson, F., Kjellman, B., and Björkstén, B. (1995). Asthma and immunoglobulin-E antibodies after respiratory syncytial virus bronchiolitis: A prospective cohort study with matched controls. *Pediatrics* 95, 500–505.

Silverstien, D. S., Owen, W. F., Gasson, J. C., DiPersio, J. F., Gold, D. W., Bina, J. C., Soberman, R., Austen, K. F. and David, J. R. (1986). Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. *J. Immunol.* 137, 3290–3294.
Welliver, R. C., Kaul, T. N. and Ogra, P. L. (1980). The appearance of cellbound IgE in respiratory tract epithelium after respiratory syncytial virus infection. *N. Engl. J. Med.* 303, 1198–1202.

Welliver, R. C., Wong, D. T., Sun, M., Middleton, E., Jr., Vaughan, R. S. and Ogra, P. L. (1981). The development of respiratory syncytial virus-specific IgE on the release of histamine in nasopharyngeal secretions after infection. *N. Engl. J. Med.* 305, 841–846.

Wimalasundera, S. S., Katz, D. R. and Chain, B. M. (1997). Characterization of the T cell response to human rhinovirus in children: Implications for understanding the immunopathology of the common cold. *J. Infect. Dis.* 176, 755–759.

Winther, B., Gwaltney, J. M., Mygind, N., Turner, R. D. and Hendley, J. O. (1986). Sites of rhinovirus recovery after point inoculation of the upper airway. *JAMA* 256, 1763–1767.

Wyde, P. R., Couch, R. B. and Mackler, B. F. (1977). Effects of low and high passage influenza virus infection in normal and nude mice. *Infect. Immun.* 15, 221–229.

Yamada, Y. K., Mager, A., Yamada, A. and Ennis, F. A. (1986). Human interferon alpha and gamma production by lymphocytes during the generation of influenza virus-specific cytotoxic T lymphocytes. *J. Gen. Virol.* 67, 2325–2334.

Yap, K. L. and Ada, G. L. (1978). The recovery of mice from influenza virus infection: Adoptive transfer of immunity with immune T lymphocytes. *Scand. J. Immunol.* 7, 389–397.

Yasumoto, K., Okamoto, S., Mukaida N., Murakami, S., Mai, M. and Matsushima, K. (1992). Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-xB-like binding sites of the interleukin 8 gene. *J. Biol. Chem.* 267, 22506–22511.

Zhu, Z., Tang, W., Ray, A., Wu, Y., Einarsson, O., Landry, M. L., Gwaltney, J., Jr. and Elias, J. A. (1996). Rhinovirus stimulation of interleukin-6 in vivo and in vitro. *J. Clin. Invest.* 97, 421–430.